The study of Destiny-BREAST04 was a third phase study, and was evaluated by the effectiveness of the bullstakan trasumab in HER2-MOD breast cancer patients [Immunohistochemistry] 1 + or with a negative fluorescent hybridization. This evidence concerns the gene ERBB2 and breast cancer.